Alphamab Oncology
HKSE: 9966.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ting Xu
- Employees
- 420
- Headquarters
- Suzhou, China
- IPO year
- 2019
- Market cap
- HK$9.7B
- Website
- https://www.alphamabonc.com
Loading 9966…
Loading profile data…Frequently asked questions about 9966
What does Alphamab Oncology (9966.HK) do?
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated i...
Where does 9966.HK trade?
Alphamab Oncology (9966.HK) trades on the Hong Kong Stock Exchange.
What sector is 9966.HK in?
Alphamab Oncology (9966.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alphamab Oncology?
Ting Xu is the chief executive officer of Alphamab Oncology (9966.HK).
Where is Alphamab Oncology headquartered?
Alphamab Oncology is headquartered in China.
Does 9966.HK pay a dividend?
Alphamab Oncology (9966.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9966.HK go public?
Alphamab Oncology (9966.HK) completed its initial public offering in 2019.